Increased oxidative stress appears to be of fundamental importance in the pathogenesis and development of several disease processes. Indeed, it is well known that reactive oxygen species (ROS) exert critical regulatory functions within the vascular wall, and it is, therefore, plausible that platelets represent a relevant target for their action. Platelet activation cascade (including receptor-mediated tethering to the endothelium, rolling, firm adhesion, aggregation, and thrombus formation) is tightly regulated. In addition to already well-defined platelet regulatory factors, ROS may participate in the regulation of platelet activation. It is already established that enhanced ROS release from the vascular wall can indirectly affect platelet activity by scavenging nitric oxide (NO), thereby decreasing the antiplatelet properties of endothelium. On the other hand, recent data suggest that platelets themselves generate ROS, which may evoke pro-thrombotic responses, triggering many biological processes participating in atherosclerosis initiation, progression, and complication. That oxidative stress may alter platelet function is conceivable when considering that antioxidants play a role in the prevention of cardiovascular disease, although the precise mechanism accounting for changes attributable to antioxidants in atherosclerosis remains unknown. It is possible that the effects of antioxidants may be a consequence of their enhancing or promoting the antiplatelet effects of NO derived from both endothelial cells and platelets. This review focuses on current knowledge regarding ROS-dependent regulation of platelet function in health and disease, and summarizes in vitro and in vivo evidence for their physiological and potential therapeutic relevance. Antioxid. Redox Signal. 17, 1447–1485.
The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force. Guidelines on platelet function testing. J Clin Pathol, 41:1322–1330. 1988.
2.
The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med, 330:1029–1035. 1994.
3.
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)Lancet, 348:1329–1339. 1996.
4.
AkbiyikF, RayDM, GettingsKF, BlumbergN, FrancisCW, PhippsRP. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood, 104:1361–1368. 2004.
5.
AlbersGW, AmarencoP, EastonJD, SaccoRL, TealP. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest, 133:630S–669S. 2008.
6.
AliFY, DavidsonSJ, MoraesLA, TravesSL, Paul-ClarkM, Bishop-BaileyD, WarnerTD, MitchellJA. Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. FASEB J, 20:326–328. 2006.
7.
AliFY, HallMG, DesvergneB, WarnerTD, MitchellJA. PPARbeta/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specific association/repression of PKCalpha—brief report. Arterioscler Thromb Vasc Biol, 29:1871–1873. 2009.
AndreP, PrasadKS, DenisCV, HeM, PapaliaJM, HynesRO, PhillipsDR, WagnerDD. CD40L stabilizes arterial thrombi by a beta3 integrin—dependent mechanism. Nat Med, 8:247–252. 2002.
10.
AngiolilloDJ, BernardoE, RamirezC, CostaMA, SabateM, Jimenez-QuevedoP, HernandezR, MorenoR, EscanedJ, AlfonsoFet al.Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol, 48:298–304. 2006.
AntoniadesC, BakogiannisC, TousoulisD, AntonopoulosAS, StefanadisC. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol, 54:669–677. 2009.
13.
AradiD, KomocsiA, VorobcsukA, RidegO, Tokes-FuzesiM, MagyarlakiT, HorvathIG, SerebruanyVL. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J, 160:543–551. 2010.
14.
AschE, PodackE. Vitronectin binds to activated human platelets and plays a role in platelet aggregation. J Clin Invest, 85:1372–1378. 1990.
15.
AukrustP, MullerF, UelandT, BergetT, AaserE, BrunsvigA, SolumNO, ForfangK, FrolandSS, GullestadL. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation, 100:614–620. 1999.
16.
BachschmidM, SchildknechtS, UllrichV. Redox regulation of vascular prostanoid synthesis by the nitric oxide-superoxide system. Biochem Biophys Res Commun, 338:536–542. 2005.
17.
BaigentC, BlackwellL, CollinsR, EmbersonJ, GodwinJ, PetoR, BuringJ, HennekensC, KearneyP, MeadeTet al.Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 373:1849–1860. 2009.
18.
BakdashN, WilliamsMS. Spatially distinct production of reactive oxygen species regulates platelet activation. Free Radic Biol Med, 45:158–166. 2008.
19.
BalduiniCL, PecciA, SavoiaA. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol, 154:161–174. 2011.
20.
BarraganP, BouvierJL, RoquebertPO, MacalusoG, CommeauP, CometB, LafontA, CamoinL, WalterU, EigenthalerM. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv, 59:295–302. 2003.
21.
BasiliS, PaciniG, GuagnanoMT, ManigrassoMR, SantilliF, PettinellaC, CiabattoniG, PatronoC, DaviG. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol, 48:2531–2538. 2006.
BaumgartnerHR. Platelet interaction with collagen fibrils in flowing blood. I. Reaction of human platelets with alpha chymotrypsin-digested subendothelium. Thromb Haemost, 37:1–16. 1977.
BeckerRC, MeadeTW, BergerPB, EzekowitzM, O'ConnorCM, VorchheimerDA, GuyattGH, MarkDB, HarringtonRA. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest, 133:776S–814S. 2008.
26.
BenndorfRA, SchwedhelmE, GnannA, TaheriR, KomG, DidieM, SteenpassA, ErgunS, BogerRH. Isoprostanes inhibit vascular endothelial growth factor-induced endothelial cell migration, tube formation, and cardiac vessel sprouting in vitro, as well as angiogenesis in vivo via activation of the thromboxane A(2) receptor: a potential link between oxidative stress and impaired angiogenesis. Circ Res, 103:1037–1046. 2008.
27.
BernardiB, GuidettiGF, CampusF, CrittendenJR, GraybielAM, BalduiniC, TortiM. The small GTPase Rap1b regulates the cross talk between platelet integrin alpha2beta1 and integrin alphaIIbbeta3. Blood, 107:2728–2735. 2006.
28.
BeumerS, HeijnenHF, MJIJ, OrlandoE, de GrootPG, SixmaJJ. Platelet adhesion to fibronectin in flow: the importance of von Willebrand factor and glycoprotein Ib. Blood, 86:3452–3460. 1995.
29.
BeversEM, ComfuriusP, ZwaalRF. Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Rev, 5:146–154. 1991.
30.
BhattDL. Intensifying platelet inhibition—navigating between Scylla and Charybdis. N Engl J Med, 357:2078–2081. 2007.
31.
BhattDL, TopolEJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA, 284:1549–1558. 2000.
32.
BlairP, RexS, VitsevaO, BeaulieuL, TanriverdiK, ChakrabartiS, HayashiC, GencoCA, IafratiM, FreedmanJE. Stimulation of Toll-like receptor 2 in human platelets induces a thromboinflammatory response through activation of phosphoinositide 3-kinase. Circ Res, 104:346–354. 2009.
33.
BlannAD, NadarSK, LipGY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J, 24:2166–2179. 2003.
34.
BonelloL, Camoin-JauL, ArquesS, BoyerC, PanagidesD, WittenbergO, SimeoniMC, BarraganP, Dignat-GeorgeF, PaganelliF. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol, 51:1404–1411. 2008.
35.
BonelloL, TantryUS, MarcucciR, BlindtR, AngiolilloDJ, BeckerR, BhattDL, CattaneoM, ColletJP, CuissetTet al.Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol, 56:919–933. 2010.
36.
BousserMG, AmarencoP, ChamorroA, FisherM, FordI, FoxKM, HennericiMG, MattleHP, RothwellPM, de CordoueAet al.Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet, 377:2013–2022. 2011.
37.
BrandtJT, PayneCD, WiviottSD, WeerakkodyG, FaridNA, SmallDS, JakubowskiJA, NaganumaH, WintersKJ. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J, 153:66.e9–16. 2007.
38.
BrarSS, ten BergJ, MarcucciR, PriceMJ, ValgimigliM, KimHS, PattiG, BreetNJ, DiSciascioG, CuissetTet al.Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol, 58:1945–1954. 2011.
39.
BrassLF. Thrombin and platelet activation. Chest, 124:18S–25S. 2003.
40.
BreetNJ, van WerkumJW, BoumanHJ, KelderJC, RuvenHJ, BalET, DeneerVH, HarmszeAM, van der HeydenJA, RensingBJet al.Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA, 303:754–762. 2010.
41.
CaiH, HarrisonDG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res, 87:840–844. 2000.
42.
CalvoD, Gomez-CoronadoD, LasuncionMA, VegaMA. CLA-1 is an 85-kD plasma membrane glycoprotein that acts as a high-affinity receptor for both native (HDL, LDL, and VLDL) and modified (OxLDL and AcLDL) lipoproteins. Arterioscler Thromb Vasc Biol, 17:2341–2349. 1997.
43.
CalzadaC, VericelE, LagardeM. Decrease in platelet reduced glutathione increases lipoxygenase activity and decreases vitamin E. Lipids, 26:696–699. 1991.
44.
CampoG, ParrinelloG, FerraresiP, LunghiB, TebaldiM, MiccoliM, MarchesiniJ, BernardiF, FerrariR, ValgimigliM. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol, 57:2474–2483. 2011.
45.
CannonCP, HustedS, HarringtonRA, SciricaBM, EmanuelssonH, PetersG, StoreyRF. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol, 50:1844–1851. 2007.
46.
CarafoliE. Calcium pump of the plasma membrane. Physiol Rev, 71:129–153. 1991.
47.
CarterMJ, FyllingCP, ParnellLK. Use of platelet rich plasma gel on wound healing: a systematic review and meta-analysis. Eplasty, 11:e38. 2011.
48.
CatellaF, HealyD, LawsonJA, FitzGeraldGA. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci U S A, 83:5861–5865. 1986.
49.
CattaneoM. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol, 24:1980–1987. 2004.
CattaneoM. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost, 35:158–167. 2009.
52.
CattaneoM, HaywardCP, MoffatKA, PuglianoMT, LiuY, MichelsonAD. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost, 7:1029. 2009.
53.
CattaneoM, PoddaGM. State of the art of new P2Y12 antagonists. Intern Emerg Med, 5:385–391. 2010.
54.
ChackalamannilS, WangY, GreenleeWJ, HuZ, XiaY, AhnHS, BoykowG, HsiehY, PalamandaJ, Agans-FantuzziJet al.Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem, 51:3061–3064. 2008.
ChenK, FebbraioM, LiW, SilversteinRL. A specific CD36-dependent signaling pathway is required for platelet activation by oxidized low-density lipoprotein. Circ Res, 102:1512–1519. 2008.
57.
ChenWH, LeePY, NgW, TseHF, LauCP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol, 43:1122–1126. 2004.
58.
ChengK, MalliarasK, ShenD, TseliouE, IontaV, SmithJ, GalangG, SunB, HoudeC, MarbanE. Intramyocardial injection of platelet gel promotes endogenous repair and augments cardiac function in rats with myocardial infarction. J Am Coll Cardiol, 59:256–264. 2012.
59.
ChintalaM, VemulapalliS, KurowskiS, SabinC, ReynoldsD, PreveteK, FriedrichG. SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys. Arterioscler Thromb Vasc Biol, 28:e138–e139. 2008.
60.
ChuSG, BeckerRC, BergerPB, BhattDL, EikelboomJW, KonkleB, MohlerER, ReillyMP, BergerJS. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost, 8:148–156. 2010.
61.
CiabattoniG, PuglieseF, DaviG, PierucciA, SimonettiBM, PatronoC. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochim Biophys Acta, 992:66–70. 1989.
62.
CinesDB, PollakES, BuckCA, LoscalzoJ, ZimmermanGA, McEverRP, PoberJS, WickTM, KonkleBA, SchwartzBSet al.Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood, 91:3527–3561. 1998.
ColemanRA, SmithWL, NarumiyaS. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev, 46:205–229. 1994.
66.
Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 324:71–86. 2002.
67.
CollerBS, ShattilSJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood, 112:3011–3025. 2008.
68.
CoughlinSR. How the protease thrombin talks to cells. Proc Natl Acad Sci U S A, 96:11023–11027. 1999.
69.
CoughlinSR. Protease-activated receptors in vascular biology. Thromb Haemost, 86:298–307. 2001.
70.
CoxD, McConkeyS. The role of platelets in the pathogenesis of cerebral malaria. Cell Mol Life Sci, 67:557–568. 2010.
71.
CrescenteM, Di CastelnuovoA, IacovielloL, VermylenJ, CerlettiC, de GaetanoG. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost, 99:14–26. 2008.
CroceK, LibbyP. Intertwining of thrombosis and inflammation in atherosclerosis. Curr Opin Hematol, 14:55–61. 2007.
74.
da Costa MartinsPA, van GilsJM, MolA, HordijkPL, ZwagingaJJ. Platelet binding to monocytes increases the adhesive properties of monocytes by up-regulating the expression and functionality of beta1 and beta2 integrins. J Leukoc Biol, 79:499–507. 2006.
75.
Dachary-PrigentJ, PasquetJM, FreyssinetJM, NurdenAT. Calcium involvement in aminophospholipid exposure and microparticle formation during platelet activation: a study using Ca2+-ATPase inhibitors. Biochemistry, 34:11625–11634. 1995.
76.
DanielJL, DangelmaierC, SmithJB. Evidence for a role for tyrosine phosphorylation of phospholipase C gamma 2 in collagen-induced platelet cytosolic calcium mobilization. Biochem J, 302,Pt 2:617–622. 1994.
77.
DaviG, AvernaM, CatalanoI, BarbagalloC, GanciA, NotarbartoloA, CiabattoniG, PatronoC. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation, 85:1792–1798. 1992.
78.
DaviG, CatalanoI, AvernaM, NotarbartoloA, StranoA, CiabattoniG, PatronoC. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med, 322:1769–1774. 1990.
79.
DaviG, ChiarelliF, SantilliF, PomilioM, VigneriS, FalcoA, BasiliS, CiabattoniG, PatronoC. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation, 107:3199–3203. 2003.
80.
DaviG, CiabattoniG, ConsoliA, MezzettiA, FalcoA, SantaroneS, PenneseE, VitacolonnaE, BucciarelliT, CostantiniFet al.In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation, 99:224–229. 1999.
81.
DaviG, FalcoA. Oxidant stress, inflammation and atherogenesis. Lupus, 14:760–764. 2005.
82.
DaviG, FalcoA, PatronoC. Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem Phys Lipids, 128:149–163. 2004.
83.
DaviG, GanciA, AvernaM, GiammarresiC, BarbagalloC, CatalanoI, CalaA, NotarbartoloA. Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia. Thromb Haemost, 74:1015–1019. 1995.
84.
DaviG, GreseleP, VioliF, BasiliS, CatalanoM, GiammarresiC, VolpatoR, NenciGG, CiabattoniG, PatronoC. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation, 96:69–75. 1997.
85.
DaviG, GuagnanoMT, CiabattoniG, BasiliS, FalcoA, MarinopiccoliM, NutiniM, SensiS, PatronoC. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA, 288:2008–2014. 2002.
86.
DaviG, PatronoC. Platelet activation and atherothrombosis. N Engl J Med, 357:2482–2494. 2007.
De BerardisG, SaccoM, StrippoliGF, PellegriniF, GrazianoG, TognoniG, NicolucciA. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ, 339:b4531. 2009.
89.
De CristofaroR, RoccaB, VitacolonnaE, FalcoA, MarchesaniP, CiabattoniG, LandolfiR, PatronoC, DaviG. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. J Thromb Haemost, 1:250–256. 2003.
90.
de GraafJC, BangaJD, MoncadaS, PalmerRM, de GrootPG, SixmaJJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation, 85:2284–2290. 1992.
91.
de la Llera-MoyaM, RothblatGH, ConnellyMA, Kellner-WeibelG, SakrSW, PhillipsMC, WilliamsDL. Scavenger receptor BI (SR-BI) mediates free cholesterol flux independently of HDL tethering to the cell surface. J Lipid Res, 40:575–580. 1999.
92.
DentJA, GalbuseraM, RuggeriZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest, 88:774–782. 1991.
93.
DiacovoTG, RothSJ, BuccolaJM, BaintonDF, SpringerTA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood, 88:146–157. 1996.
94.
DiChiaraJ, BlidenKP, TantryUS, HamedMS, AntoninoMJ, SuarezTA, BailonO, SinglaA, GurbelPA. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes, 56:3014–3019. 2007.
95.
DienerHC, BogousslavskyJ, BrassLM, CimminielloC, CsibaL, KasteM, LeysD, Matias-GuiuJ, RupprechtHJ. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet, 364:331–337. 2004.
96.
DixonLJ, HughesSM, RooneyK, MaddenA, DevineA, LeaheyW, HenryW, JohnstonGD, McVeighGE. Increased superoxide production in hypertensive patients with diabetes mellitus: role of nitric oxide synthase. Am J Hypertens, 18:839–843. 2005.
97.
DraganiA, PascaleS, RecchiutiA, MattoscioD, LattanzioS, PetrucciG, MucciL, FerranteE, HabibA, RanellettiFOet al.The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood, 115:1054–1061. 2010.
98.
DuX. Signaling and regulation of the platelet glycoprotein Ib-IX-V complex. Curr Opin Hematol, 14:262–269. 2007.
99.
EikelboomJW, HirshJ, WeitzJI, JohnstonM, YiQ, YusufS. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation, 105:1650–1655. 2002.
100.
EikelboomJW, O'DonnellM. Using aspirin to prevent cognitive decline. BMJ, 337:a958. 2008.
101.
EssexDW. The role of thiols and disulfides in platelet function. Antioxid Redox Signal, 6:736–746. 2004.
102.
EssexDW, LiM, MillerA, FeinmanRD. Protein disulfide isomerase and sulfhydryl-dependent pathways in platelet activation. Biochemistry, 40:6070–6075. 2001.
103.
EvertsPA, KnapeJT, WeibrichG, SchonbergerJP, HoffmannJ, OverdevestEP, BoxHA, van ZundertA. Platelet-rich plasma and platelet gel: a review. J Extra Corpor Technol, 38:174–187. 2006.
104.
EzumiY, ShindohK, TsujiM, TakayamaH. Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets. J Exp Med, 188:267–276. 1998.
105.
FerroniP, BasiliS, FalcoA, DaviG. Oxidant stress and platelet activation in hypercholesterolemia. Antioxid Redox Signal, 6:747–756. 2004.
106.
FerroniP, MartiniF, RiondinoS, La FarinaF, MagnaperaA, CiattiF, GuadagniF. Soluble P-selectin as a marker of in vivo platelet activation. Clin Chim Acta, 399:88–91. 2009.
107.
FlemingI, SchulzC, FichtlschererB, KempBE, FisslthalerB, BusseR. AMP-activated protein kinase (AMPK) regulates the insulin-induced activation of the nitric oxide synthase in human platelets. Thromb Haemost, 90:863–871. 2003.
108.
ForstermannU. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med, 5:338–349. 2008.
109.
ForstermannU. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch, 459:923–939. 2010.
110.
ForstermannU, NakaneM, TraceyWR, PollockJS. Isoforms of nitric oxide synthase: functions in the cardiovascular system. Eur Heart J, 14,Suppl I:10–15. 1993.
FreedmanJE, LoscalzoJ, BarnardMR, AlpertC, KeaneyJF, MichelsonAD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest, 100:350–356. 1997.
113.
FrenettePS, DenisCV, WeissL, JurkK, SubbaraoS, KehrelB, HartwigJH, VestweberD, WagnerDD. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med, 191:1413–1422. 2000.
114.
FurieKL, KasnerSE, AdamsRJ, AlbersGW, BushRL, FaganSC, HalperinJL, JohnstonSC, KatzanI, KernanWNet al.Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke, 42:227–276. 2011.
115.
GachetC. P2 receptors, platelet function and pharmacological implications. Thromb Haemost, 99:466–472. 2008.
116.
GarlichsCD, JohnS, SchmeisserA, EskafiS, StumpfC, KarlM, Goppelt-StruebeM, SchmiederR, DanielWG. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation, 104:2395–2400. 2001.
117.
GawazM, LangerH, MayAE. Platelets in inflammation and atherogenesis. J Clin Invest, 115:3378–3384. 2005.
118.
GiannarelliC, ZafarMU, BadimonJJ. Prostanoid and TP-receptors in atherothrombosis: is there a role for their antagonism?Thromb Haemost, 104:949–954. 2010.
119.
GibbinsJM, OkumaM, FarndaleR, BarnesM, WatsonSP. Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain. FEBS Lett, 413:255–259. 1997.
GodynaS, Diaz-RicartM, ArgravesWS. Fibulin-1 mediates platelet adhesion via a bridge of fibrinogen. Blood, 88:2569–2577. 1996.
122.
GoodwinDC, GuntherMR, HsiLC, CrewsBC, ElingTE, MasonRP, MarnettLJ. Nitric oxide trapping of tyrosyl radicals generated during prostaglandin endoperoxide synthase turnover. Detection of the radical derivative of tyrosine 385. J Biol Chem, 273:8903–8909. 1998.
123.
GotoS, IkedaY, SaldivarE, RuggeriZM. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest, 101:479–486. 1998.
124.
GraySJ, HeptinstallS. Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP. Eur J Pharmacol, 194:63–70. 1991.
125.
GreseleP, CatalanoM, GiammarresiC, VolpatoR, TerminiR, CiabattoniG, NenciGG, DaviG. Platelet activation markers in patients with peripheral arterial disease—a prospective comparison of different platelet function tests. Thromb Haemost, 78:1434–1437. 1997.
126.
GreseleP, CerlettiC, GuglielminiG, PignatelliP, de GaetanoG, VioliF. Effects of resveratrol and other wine polyphenols on vascular function: an update. J Nutr Biochem, 22:201–211. 2011.
127.
GurbelPA, BeckerRC, MannKG, SteinhublSR, MichelsonAD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol, 50:1822–1834. 2007.
128.
GuthikondaS, AlviarCL, VaduganathanM, ArikanM, TellezA, DeLaoT, GranadaJF, DongJF, KleimanNS, LevEI. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol, 52:743–749. 2008.
129.
GuthikondaS, LevEI, PatelR, DeLaoT, BergeronAL, DongJF, KleimanNS. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost, 5:490–496. 2007.
130.
HambergM, SvenssonJ, SamuelssonB. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A, 72:2994–2998. 1975.
131.
HarperMT, PooleAW. Store-operated calcium entry and non-capacitative calcium entry have distinct roles in thrombin-induced calcium signalling in human platelets. Cell Calcium, 50:351–358. 2011.
132.
HarrisonD, GriendlingKK, LandmesserU, HornigB, DrexlerH. Role of oxidative stress in atherosclerosis. Am J Cardiol, 91:7A–11A. 2003.
133.
HarrisonP. Platelet function analysis. Blood Rev, 19:111–123. 2005.
134.
HarrisonP. Assessment of platelet function in the laboratory. Hamostaseologie, 29:25–31. 2009.
135.
HarrisonP, KeelingD. Clinical tests of platelet function. Platelets, 2ndMichelsonAD. San Diego, CA: Elsevier/Academic Press, 2007; 445–447.
136.
HarrisonP, MackieI, MumfordA, BriggsC, LiesnerR, WinterM, MachinS. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol, 155:30–44. 2011.
137.
HattoriY, SuzukiM, HattoriS, KasaiK. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia, 46:1543–1549. 2003.
HaywardCP, HarrisonP, CattaneoM, OrtelTL, RaoAK. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost, 4:312–319. 2006.
HeemskerkJW, KuijpersMJ, MunnixIC, SiljanderPR. Platelet collagen receptors and coagulation. A characteristic platelet response as possible target for antithrombotic treatment. Trends Cardiovasc Med, 15:86–92. 2005.
142.
HeemskerkJW, WillemsGM, RookMB, SageSO. Ragged spiking of free calcium in ADP-stimulated human platelets: regulation of puff-like calcium signals in vitro and ex vivo. J Physiol, 535:625–635. 2001.
143.
HeeschenC, DimmelerS, HammCW, van den BrandMJ, BoersmaE, ZeiherAM, SimoonsML. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med, 348:1104–1111. 2003.
144.
HekimsoyZ, PayzinB, OrnekT, KandoganG. Mean platelet volume in Type 2 diabetic patients. J Diabetes Complications, 18:173–176. 2004.
145.
HennV, SlupskyJR, GrafeM, AnagnostopoulosI, ForsterR, Muller-BerghausG, KroczekRA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature, 391:591–594. 1998.
146.
HigashiY, NomaK, YoshizumiM, KiharaY. Endothelial function and oxidative stress in cardiovascular diseases. Circ J, 73:411–418. 2009.
147.
HindriksG, IjsseldijkMJ, SonnenbergA, SixmaJJ, de GrootPG. Platelet adhesion to laminin: role of Ca2+ and Mg2+ ions, shear rate, and platelet membrane glycoproteins. Blood, 79:928–935. 1992.
148.
HoffmanM, MonroeDM3rd. A cell-based model of hemostasis. Thromb Haemost, 85:958–965. 2001.
149.
HollanderJE, MuttrejaMR, DalesandroMR, ShoferFS. Risk stratification of emergency department patients with acute coronary syndromes using P-selectin. J Am Coll Cardiol, 34:95–105. 1999.
HuangMM, BolenJB, BarnwellJW, ShattilSJ, BruggeJS. Membrane glycoprotein IV (CD36) is physically associated with the Fyn, Lyn, and Yes protein-tyrosine kinases in human platelets. Proc Natl Acad Sci U S A, 88:7844–7848. 1991.
152.
HustedS, EmanuelssonH, HeptinstallS, SandsetPM, WickensM, PetersG. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J, 27:1038–1047. 2006.
153.
InoueO, Suzuki-InoueK, DeanWL, FramptonJ, WatsonSP. Integrin alpha2beta1 mediates outside-in regulation of platelet spreading on collagen through activation of Src kinases and PLCgamma2. J Cell Biol, 160:769–780. 2003.
154.
JacksonMR. Fibrin sealants in surgical practice: an overview. Am J Surg, 182:1S–7S. 2001.
155.
JacksonSP, SchoenwaelderSM, GoncalvesI, NesbittWS, YapCL, WrightCE, KencheV, AndersonKE, DopheideSM, YuanYet al.PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med, 11:507–514. 2005.
156.
JaumdallyRJ, VarmaC, BlannAD, MacFadyenRJ, LipGY. Platelet activation in coronary artery disease: intracardiac vs peripheral venous levels and the effects of angioplasty. Chest, 132:1532–1539. 2007.
157.
JenningsI, WoodsTA, KitchenS, WalkerID. Platelet function testing: practice among UK National External Quality Assessment Scheme for Blood Coagulation participants, 2006. J Clin Pathol, 61:950–954. 2008.
158.
JenningsLK, EarhartA, BeckerRC, ReydermanL, VeltriE, HarringtonRA. Thrombin receptor antagonist (TRA;SCH530348) is a selective, potent inhibitor of PAR1 activity with predictable pharmacokinetics. Circulation, 116:II_674. 2007.
159.
JilmaB. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med, 138:152–163. 2001.
160.
JinJ, DanielJL, KunapuliSP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem, 273:2030–2034. 1998.
161.
JinchuanY, ZongguiW, JinmingC, LiL, XiantaoK. Upregulation of CD40—CD40 ligand system in patients with diabetes mellitus. Clin Chim Acta, 339:85–90. 2004.
162.
JungSM, MoroiM. Signal-transducing mechanisms involved in activation of the platelet collagen receptor integrin alpha(2)beta(1)J Biol Chem, 275:8016–8026. 2000.
163.
JurkK, ClemetsonKJ, de GrootPG, BroddeMF, SteinerM, SavionN, VaronD, SixmaJJ, Van AkenH, KehrelBE. Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB J, 17:1490–1492. 2003.
164.
KahnML, Nakanishi-MatsuiM, ShapiroMJ, IshiharaH, CoughlinSR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest, 103:879–887. 1999.
165.
KatoK, KanajiT, RussellS, KunickiTJ, FurihataK, KanajiS, MarcheseP, ReiningerA, RuggeriZM, WareJ. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood, 102:1701–1707. 2003.
166.
KatoY, KitaY, Hirasawa-TaniyamaY, NishioM, MiharaK, ItoK, YamanakaT, SekiJ, MiyataS, MutohS. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol, 473:163–169. 2003.
167.
KatopodisJN, KolodnyL, JyW, HorstmanLL, De MarchenaEJ, TaoJG, HaynesDH, AhnYS. Platelet microparticles and calcium homeostasis in acute coronary ischemias. Am J Hematol, 54:95–101. 1997.
KeaneyJFJr., LarsonMG, VasanRS, WilsonPW, LipinskaI, CoreyD, MassaroJM, SutherlandP, VitaJA, BenjaminEJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol, 23:434–439. 2003.
170.
KerriganSW, ClarkeN, LoughmanA, MeadeG, FosterTJ, CoxD. Molecular basis for Staphylococcus aureus-mediated platelet aggregate formation under arterial shear in vitro. Arterioscler Thromb Vasc Biol, 28:335–340. 2008.
171.
KerriganSW, CoxD. Platelet-bacterial interactions. Cell Mol Life Sci, 67:513–523. 2010.
172.
KerriganSW, DouglasI, WrayA, HeathJ, ByrneMF, FitzgeraldD, CoxD. A role for glycoprotein Ib in Streptococcus sanguis-induced platelet aggregation. Blood, 100:509–516. 2002.
173.
KhazaeiM, Moien-AfshariF, LaherI. Vascular endothelial function in health and diseases. Pathophysiology, 15:49–67. 2008.
174.
KhetawatG, FaradayN, NealenML, VijayanKV, BoltonE, NogaSJ, BrayPF. Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood, 95:2289–2296. 2000.
175.
KlovaiteJ, BennM, YazdanyarS, NordestgaardBG. High platelet volume and increased risk of myocardial infarction: 39,531 participants from the general population. J Thromb Haemost, 9:49–56. 2010.
176.
KriegerM. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest, 108:793–797. 2001.
177.
KrotzF, SohnHY, PohlU. Reactive oxygen species: players in the platelet game. Arterioscler Thromb Vasc Biol, 24:1988–1996. 2004.
178.
KushnerFG, HandM, SmithSJr., KingSB3rd, AndersonJL, AntmanEM, BaileySR, BatesER, BlankenshipJC, CaseyDEJr.et al.2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 120:2271–2306. 2009.
179.
LahavJ, Gofer-DadoshN, LuboshitzJ, HessO, ShaklaiM. Protein disulfide isomerase mediates integrin-dependent adhesion. FEBS Lett, 475:89–92. 2000.
LarsenE, CeliA, GilbertGE, FurieBC, ErbanJK, BonfantiR, WagnerDD, FurieB. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell, 59:305–312. 1989.
LeivaA, VerdejoH, BenitezML, MartinezA, BussoD, RigottiA. Mechanisms regulating hepatic SR-BI expression and their impact on HDL metabolism. Atherosclerosis, 217:299–307. 2011.
185.
Levy-ToledanoS. Platelet signal transduction pathways: could we organize them into a ‘hierarchy’?Haemostasis, 29:4–15. 1999.
186.
LiZ, DelaneyMK, O'BrienKA, DuX. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol, 30:2341–2349. 2010.
187.
LiZ, ZhangG, Le BretonGC, GaoX, MalikAB, DuX. Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. J Biol Chem, 278:30725–30731. 2003.
188.
LiaoJK. Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?Circulation, 115:1615–1621. 2007.
189.
LibbyP, SimonDI. Inflammation and thrombosis: the clot thickens. Circulation, 103:1718–1720. 2001.
LiuM, WallmonA, Olsson-MortlockC, WallinR, SaldeenT. Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms. Am J Clin Nutr, 77:700–706. 2003.
192.
LiuY, BubolzAH, MendozaS, ZhangDX, GuttermanDD. H2O2 is the transferrable factor mediating flow-induced dilation in human coronary arterioles. Circ Res, 108:566–573. 2011.
193.
LordkipanidzeM, PharandC, SchampaertE, TurgeonJ, PalisaitisDA, DiodatiJG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J, 28:1702–1708. 2007.
194.
LovaP, PaganiniS, HirschE, BarberisL, WymannM, SinigagliaF, BalduiniC, TortiM. A selective role for phosphatidylinositol 3,4,5-trisphosphate in the Gi-dependent activation of platelet Rap1B. J Biol Chem, 278:131–138. 2003.
195.
LowenbergEC, MeijersJC, LeviM. Platelet-vessel wall interaction in health and disease. Neth J Med, 68:242–251. 2010.
196.
MalininA, PokovA, SwaimL, KotobM, SerebruanyV. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol, 28:315–322. 2006.
197.
MarcusAJ, SilkST, SafierLB, UllmanHL. Superoxide production and reducing activity in human platelets. J Clin Invest, 59:149–158. 1977.
198.
MaschbergerP, BauerM, Baumann-SiemonsJ, ZanglKJ, NegrescuEV, ReiningerAJ, SiessW. Mildly oxidized low density lipoprotein rapidly stimulates via activation of the lysophosphatidic acid receptor Src family and Syk tyrosine kinases and Ca2+ influx in human platelets. J Biol Chem, 275:19159–19166. 2000.
199.
MassbergS, BrandK, GrunerS, PageS, MullerE, MullerI, BergmeierW, RichterT, LorenzM, KonradIet al.A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med, 196:887–896. 2002.
200.
MayJM. How does ascorbic acid prevent endothelial dysfunction?Free Radic Biol Med, 28:1421–1429. 2000.
201.
McCartyOJ, LarsonMK, AugerJM, KaliaN, AtkinsonBT, PearceAC, RufS, HendersonRB, TybulewiczVL, MacheskyLMet al.Rac1 is essential for platelet lamellipodia formation and aggregate stability under flow. J Biol Chem, 280:39474–39484. 2005.
202.
McEverRP, BecksteadJH, MooreKL, Marshall-CarlsonL, BaintonDF. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest, 84:92–99. 1989.
203.
McFarlandJG. Laboratory investigation of drug-induced immune thrombocytopenias. Transfus Med Rev, 7:275–287. 1993.
204.
MegaJL, SimonT, ColletJP, AndersonJL, AntmanEM, BlidenK, CannonCP, DanchinN, GiustiB, GurbelPet al.Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA, 304:1821–1830. 2010.
205.
MichelsonAD. Methods for the measurement of platelet function. Am J Cardiol, 103:20A–26A. 2009.
206.
MichelsonAD, BarnardMR, HechtmanHB, MacGregorH, ConnollyRJ, LoscalzoJ, ValeriCR. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A, 93:11877–11882. 1996.
MiuraH, BosnjakJJ, NingG, SaitoT, MiuraM, GuttermanDD. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ Res, 92:e31–e40. 2003.
209.
MontuschiP, BarnesPJ, RobertsLJ2nd. Isoprostanes: markers and mediators of oxidative stress. FASEB J, 18:1791–1800. 2004.
210.
MoroL, ReineriS, PirandaD, PietrapianaD, LovaP, BertoniA, GrazianiA, DefilippiP, CanobbioI, TortiMet al.Nongenomic effects of 17beta-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor beta and Src kinase. Blood, 105:115–121. 2005.
211.
MorrowJD. Is oxidant stress a connection between obesity and atherosclerosis?Arterioscler Thromb Vasc Biol, 23:368–370. 2003.
212.
MorrowJD, AwadJA, BossHJ, BlairIA, RobertsLJ2nd. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci U S A, 89:10721–10725. 1992.
213.
MorrowJD, HillKE, BurkRF, NammourTM, BadrKF, RobertsLJ2nd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A, 87:9383–9387. 1990.
214.
MorrowJD, RobertsLJ. The isoprostanes: their role as an index of oxidant stress status in human pulmonary disease. Am J Respir Crit Care Med, 166:S25–S30. 2002.
215.
MurthyM, RaoGH, RobinsonP, ReddyS. Influx of extracellular calcium and agonist-coupling appear essential for the activation of thromboxane A2-dependent phospholipase A2 in human platelets. Prostaglandins Leukot Essent Fatty Acids, 53:31–39. 1995.
216.
MusiekES, YinH, MilneGL, MorrowJD. Recent advances in the biochemistry and clinical relevance of the isoprostane pathway. Lipids, 40:987–994. 2005.
NieswandtB, BrakebuschC, BergmeierW, SchulteV, BouvardD, Mokhtari-NejadR, LindhoutT, HeemskerkJW, ZirngiblH, FasslerR. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J, 20:2120–2130. 2001.
O'BrienLM, WalshEJ, MasseyRC, PeacockSJ, FosterTJ. Staphylococcus aureus clumping factor B (ClfB) promotes adherence to human type I cytokeratin 10: implications for nasal colonization. Cell Microbiol, 4:759–770. 2002.
221.
PandeyD, GoyalP, DwivediS, SiessW. Unraveling a novel Rac1-mediated signaling pathway that regulates cofilin dephosphorylation and secretion in thrombin-stimulated platelets. Blood, 114:415–424. 2009.
222.
PatronoC. Measurement of thromboxane biosynthesis in man. Eicosanoids, 2:249–251. 1989.
223.
PatronoC. Aspirin as an antiplatelet drug. N Engl J Med, 330:1287–1294. 1994.
224.
PatronoC, BaigentC, HirshJ, RothG. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest, 133:199S–233S. 2008.
PatronoC, FitzGeraldGA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol, 17:2309–2315. 1997.
227.
PatronoC, Garcia RodriguezLA, LandolfiR, BaigentC. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med, 353:2373–2383. 2005.
228.
PayrastreB, MissyK, TrumelC, BodinS, PlantavidM, ChapH. The integrin alpha IIb/beta 3 in human platelet signal transduction. Biochem Pharmacol, 60:1069–1074. 2000.
229.
PeerschkeEI. Regulation of platelet aggregation by post-fibrinogen binding events. Insights provided by dithiothreitol-treated platelets. Thromb Haemost, 73:862–867. 1995.
230.
PhiliposeS, KonyaV, SreckovicI, MarscheG, LippeIT, PeskarBA, HeinemannA, SchuligoiR. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation. Arterioscler Thromb Vasc Biol, 30:2416–2423. 2010.
PignatelliP, SanguigniV, PaolaSG, Lo CocoE, LentiL, VioliF. Vitamin C inhibits platelet expression of CD40 ligand. Free Radic Biol Med, 38:1662–1666. 2005.
233.
PodrezEA, ByzovaTV, FebbraioM, SalomonRG, MaY, ValiyaveettilM, PoliakovE, SunM, FintonPJ, CurtisBRet al.Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med, 13:1086–1095. 2007.
234.
PrasadKS, AndreP, HeM, BaoM, ManganelloJ, PhillipsDR. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci U S A, 100:12367–12371. 2003.
235.
PraticoD, LawsonJA, RokachJ, FitzGeraldGA. The isoprostanes in biology and medicine. Trends Endocrinol Metab, 12:243–247. 2001.
236.
PraticoD, RokachJ, LawsonJ, FitzGeraldGA. F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. Chem Phys Lipids, 128:165–171. 2004.
237.
PraticoD, SmythEM, VioliF, FitzGeraldGA. Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms. J Biol Chem, 271:14916–14924. 1996.
238.
PriceMJ, AngiolilloDJ, TeirsteinPS, LillieE, ManoukianSV, BergerPB, TanguayJF, CannonCP, TopolEJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation, 124:1132–1137. 2011.
239.
PriceMJ, BergerPB, TeirsteinPS, TanguayJF, AngiolilloDJ, SpriggsD, PuriS, RobbinsM, GarrattKN, BertrandOFet al.Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA, 305:1097–1105. 2011.
240.
PriceMJ, EndemannS, GollapudiRR, ValenciaR, StinisCT, LevisayJP, ErnstA, SawhneyNS, SchatzRA, TeirsteinPS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J, 29:992–1000. 2008.
241.
QueenLR, XuB, HorinouchiK, FisherI, FerroA. beta(2)-adrenoceptors activate nitric oxide synthase in human platelets. Circ Res, 87:39–44. 2000.
242.
RadomskiMW, PalmerRM, MoncadaS. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A, 87:5193–5197. 1990.
243.
RandriamboavonjyV, FlemingI. Endothelial nitric oxide synthase (eNOS) in platelets: how is it regulated and what is it doing there?Pharmacol Rep, 57,Suppl:59–65. 2005.
244.
RayDM, SpinelliSL, PollockSJ, MurantTI, O'BrienJJ, BlumbergN, FrancisCW, TaubmanMB, PhippsRP. Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles. Thromb Haemost, 99:86–95. 2008.
245.
ReillyIA, FitzGeraldGA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood, 69:180–186. 1987.
246.
ReinerAP, CarlsonCS, ThyagarajanB, RiederMJ, PolakJF, SiscovickDS, NickersonDA, JacobsDRJr., GrossMD. Soluble P-selectin, SELP polymorphisms, and atherosclerotic risk in European-American and African-African young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler Thromb Vasc Biol, 28:1549–1555. 2008.
247.
RenQ, YeS, WhiteheartSW. The platelet release reaction: just when you thought platelet secretion was simple. Curr Opin Hematol, 15:537–541. 2008.
248.
ReyC, VericelE, NemozG, ChenW, ChapuyP, LagardeM. Purification and characterization of glutathione peroxidase from human blood platelets. Age-related changes in the enzyme. Biochim Biophys Acta, 1226:219–224. 1994.
249.
RidkerPM, BuringJE, RifaiN. Soluble P-selectin and the risk of future cardiovascular events. Circulation, 103:491–495. 2001.
250.
RiondinoS, MartiniF, La FarinaF, SpilaA, GuadagniF, FerroniP. Increased plasma levels of soluble CD40 ligand correlate with platelet activation markers and underline the need for standardized pre-analytical conditions. Clin Biochem, 43:666–670. 2010.
251.
RiveraJ, LozanoML, Navarro-NunezL, VicenteV. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica, 94:700–711. 2009.
252.
RoccaB, PatronoC. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost, 3:1597–1602. 2005.
253.
RosadoJA, BrownlowSL, SageSO. Endogenously expressed Trp1 is involved in store-mediated Ca2+ entry by conformational coupling in human platelets. J Biol Chem, 277:42157–42163. 2002.
254.
RosadoJA, LopezJJ, HarperAG, HarperMT, RedondoPC, ParienteJA, SageSO, SalidoGM. Two pathways for store-mediated calcium entry differentially dependent on the actin cytoskeleton in human platelets. J Biol Chem, 279:29231–29235. 2004.
255.
RosadoJA, SageSO. Platelet signaling: calcium. Platelets in Thrombotic And Non-Thrombotic Disorders. Cambridge University Press, 2002; 260–271.
256.
RuggeriZM. The role of von Willebrand factor in thrombus formation. Thromb Res, 120,Suppl 1:S5–S9. 2007.
257.
RuggeriZM. Platelet adhesion under flow. Microcirculation, 16:58–83. 2009.
258.
RuggeriZM, DentJA, SaldivarE. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood, 94:172–178. 1999.
259.
RuggeriZM, OrjeJN, HabermannR, FedericiAB, ReiningerAJ. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood, 108:1903–1910. 2006.
260.
SaccoRL, DienerHC, YusufS, CottonD, OunpuuS, LawtonWA, PaleschY, MartinRH, AlbersGW, BathPet al.Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med, 359:1238–1251. 2008.
261.
SadlerJE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem, 67:395–424. 1998.
262.
SanguigniV, PignatelliP, LentiL, FerroD, BelliaA, CarnevaleR, TesauroM, SorgeR, LauroR, VioliF. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation, 111:412–419. 2005.
263.
SantilliF, BasiliS, FerroniP, DaviG. CD40/CD40L system and vascular disease. Intern Emerg Med, 2:256–268. 2007.
264.
SantilliF, DaviG, BasiliS, LattanzioS, CavoniA, GuizzardiG, De FeudisL, TraisciG, PettinellaC, PalosciaLet al.Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. J Thromb Haemost, 8:914–922. 2010.
265.
SantilliF, DaviG, ConsoliA, CipolloneF, MezzettiA, FalcoA, TaraborelliT, DevangelioE, CiabattoniG, BasiliSet al.Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol, 47:391–397. 2006.
266.
SantilliF, FormosoG, SbracciaP, AvernaM, MiccoliR, Di FulvioP, GanciA, PulizziN, LattanzioS, CiabattoniGet al.Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost, 8:828–837. 2010.
267.
SantilliF, RoccaB, De CristofaroR, LattanzioS, PietrangeloL, HabibA, PettinellaC, RecchiutiA, FerranteE, CiabattoniGet al.Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance”J Am Coll Cardiol, 53:667–677. 2009.
268.
SavageB, SaldivarE, RuggeriZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell, 84:289–297. 1996.
269.
ScharfRE, RahmanMM, SeidelH. The impact and management of acquired platelet dysfunction. Hamostaseologie, 31:28–40. 2011.
270.
SchildknechtS, van der LooB, WeberK, TiefenthalerK, DaiberA, BachschmidMM. Endogenous peroxynitrite modulates PGHS-1-dependent thromboxane A2 formation and aggregation in human platelets. Free Radic Biol Med, 45:512–520. 2008.
271.
SchonbeckU, VaroN, LibbyP, BuringJ, RidkerPM. Soluble CD40L and cardiovascular risk in women. Circulation, 104:2266–2268. 2001.
272.
SchwedhelmE, BierendA, MaasR, TrinksR, KomGD, TsikasD, BogerRH. Redox-generated isoprostanes are associated with residual platelet activity in aspirin-treated patients with stable coronary heart disease. J Thromb Haemost, 8:2662–2670. 2010.
273.
SerebruanyVL, KogushiM, Dastros-PiteiD, FlatherM, BhattDL. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost, 102:111–119. 2009.
274.
SharmaG, BergerJS. Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data. J Thromb Thrombolysis, 32:201–208. 2011.
275.
ShattilSJ, HoxieJA, CunninghamM, BrassLF. Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. J Biol Chem, 260:11107–11114. 1985.
ShattilSJ, NewmanPJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood, 104:1606–1615. 2004.
278.
ShawKT, MawjiY, StevensonMM, KongshavnPA. Cells within the vascular system capable of mediating trypanocidal activity in vitro. Infect Immun, 59:3143–3150. 1991.
279.
SibbingD, BraunS, MorathT, MehilliJ, VogtW, SchomigA, KastratiA, von BeckerathN. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol, 53:849–856. 2009.
280.
SibbingD, ByrneRA, BernlochnerI, KastratiA. High platelet reactivity and clinical outcome - fact and fiction. Thromb Haemost, 106:191–202. 2011.
281.
SignorelloMG, PascaleR, LeonciniG. Transport of L-arginine and nitric oxide formation in human platelets. Eur J Biochem, 270:2005–2012. 2003.
282.
SimonT, VerstuyftC, Mary-KrauseM, QuteinehL, DrouetE, MeneveauN, StegPG, FerrieresJ, DanchinN, BecquemontL. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med, 360:363–375. 2009.
283.
SinglaA, AntoninoMJ, BlidenKP, TantryUS, GurbelPA. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J, 158:784.e781–e786. 2009.
284.
SmithJW, SteinhublSR, LincoffAM, ColemanJC, LeeTT, HillmanRS, CollerBS. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation, 99:620–625. 1999.
285.
SmithSCJr., AllenJ, BlairSN, BonowRO, BrassLM, FonarowGC, GrundySM, HiratzkaL, JonesD, KrumholzHMet al.AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation, 113:2363–2372. 2006.
286.
SouletC, GendreauS, MissyK, BenardV, PlantavidM, PayrastreB. Characterisation of Rac activation in thrombin- and collagen-stimulated human blood platelets. FEBS Lett, 507:253–258. 2001.
287.
SteinhublSR, TalleyJD, BradenGA, TchengJE, CasterellaPJ, MoliternoDJ, NavettaFI, BergerPB, PopmaJJ, DangasGet al.Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation, 103:2572–2578. 2001.
288.
StenbergPE, McEverRP, ShumanMA, JacquesYV, BaintonDF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol, 101:880–886. 1985.
289.
StokesKY, CalahanL, HamricCM, RussellJM, GrangerDN. CD40/CD40L contributes to hypercholesterolemia-induced microvascular inflammation. Am J Physiol Heart Circ Physiol, 296:H689–H697. 2009.
290.
StokesKY, CalahanL, RussellJM, GurwaraS, GrangerDN. Role of platelets in hypercholesterolemia-induced leukocyte recruitment and arteriolar dysfunction. Microcirculation, 13:377–388. 2006.
291.
StokesKY, RussellJM, JenningsMH, AlexanderJS, GrangerDN. Platelet-associated NAD(P)H oxidase contributes to the thrombogenic phenotype induced by hypercholesterolemia. Free Radic Biol Med, 43:22–30. 2007.
292.
StrasselC, MoogS, BaasMJ, CazenaveJP, LanzaF. Biosynthesis of platelet glycoprotein V expressed as a single subunit or in association with GPIb-IX. Eur J Biochem, 271:3671–3677. 2004.
293.
Suzuki-InoueK, YatomiY, AsazumaN, KainohM, TanakaT, SatohK, OzakiY. Rac, a small guanosine triphosphate-binding protein, and p21-activated kinase are activated during platelet spreading on collagen-coated surfaces: roles of integrin alpha(2)beta(1)Blood, 98:3708–3716. 2001.
294.
TadokoroS, ShattilSJ, EtoK, TaiV, LiddingtonRC, de PeredaJM, GinsbergMH, CalderwoodDA. Talin binding to integrin beta tails: a final common step in integrin activation. Science, 302:103–106. 2003.
ThomasSR, WittingPK, DrummondGR. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal, 10:1713–1765. 2008.
297.
TschoepeD, RoesenP, EsserJ, SchwippertB, NieuwenhuisHK, KehrelB, GriesFA. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost, 17:433–438. 1991.
298.
TsiaraS, ElisafM, JagroopIA, MikhailidisDP. Platelets as predictors of vascular risk: is there a practical index of platelet activity?Clin Appl Thromb Hemost, 9:177–190. 2003.
299.
UrbichC, DernbachE, AicherA, ZeiherAM, DimmelerS. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation, 106:981–986. 2002.
300.
UssarS, WangHV, LinderS, FasslerR, MoserM. The Kindlins: subcellular localization and expression during murine development. Exp Cell Res, 312:3142–3151. 2006.
ValkoM, LeibfritzD, MoncolJ, CroninMT, MazurM, TelserJ. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol, 39:44–84. 2007.
303.
VallanceP, LeiperJ. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol, 24:1023–1030. 2004.
304.
Van de WalleGR, SchoolmeesterA, IserbytBF, CosemansJM, HeemskerkJW, HoylaertsMF, NurdenA, VanhoorelbekeK, DeckmynH. Activation of alphaIIbbeta3 is a sufficient but also an imperative prerequisite for activation of alpha2beta1 on platelets. Blood, 109:595–602. 2007.
305.
van der ZeePM, BiroE, KoY, de WinterRJ, HackCE, SturkA, NieuwlandR. P-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem, 52:657–664. 2006.
VaroN, VicentD, LibbyP, NuzzoR, Calle-PascualAL, BernalMR, Fernandez-CruzA, VevesA, JarolimP, VaroJJet al.Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation, 107:2664–2669. 2003.
309.
VergeerM, KorporaalSJ, FranssenR, MeursI, OutR, HovinghGK, HoekstraM, SiertsJA, Dallinga-ThieGM, MotazackerMMet al.Genetic variant of the scavenger receptor BI in humans. N Engl J Med, 364:136–145. 2011.
310.
VidalC, SpauldingC, PicardF, SchaisonF, MelleJ, WeberS, Fontenay-RoupieM. Flow cytometry detection of platelet procoagulation activity and microparticles in patients with unstable angina treated by percutaneous coronary angioplasty and stent implantation. Thromb Haemost, 86:784–790. 2001.
311.
VizioliL, MuscariS, MuscariA. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract, 63:1509–1515. 2009.
312.
von HundelshausenP, WeberC. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res, 100:27–40. 2007.
313.
WallJE, Buijs-WiltsM, ArnoldJT, WangW, WhiteMM, JenningsLK, JacksonCW. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br J Haematol, 89:380–385. 1995.
314.
WallentinL, BeckerRC, BudajA, CannonCP, EmanuelssonH, HeldC, HorrowJ, HustedS, JamesS, KatusHet al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 361:1045–1057. 2009.
315.
WallentinL, JamesS, StoreyRF, ArmstrongM, BarrattBJ, HorrowJ, HustedS, KatusH, StegPG, ShahSHet al.Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet, 376:1320–1328. 2010.
316.
WangJC, Aucoin-BarryD, ManuelianD, MonbouquetteR, ReismanM, GrayW, BlockPC, BlockEH, LadenheimM, SimonDI. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol, 92:1492–1494. 2003.
317.
WangTH, BhattDL, TopolEJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J, 27:647–654. 2006.
WatsonSP, AugerJM, McCartyOJ, PearceAC. GPVI and integrin alphaIIb beta3 signaling in platelets. J Thromb Haemost, 3:1752–1762. 2005.
320.
WeissHJ, SussmanII, HoyerLW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest, 60:390–404. 1977.
321.
WeitzJI, HirshJ, SamamaMM. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Chest, 133:234S–256S. 2008.
322.
WeyrichAS, ZimmermanGA. Platelets: signaling cells in the immune continuum. Trends Immunol, 25:489–495. 2004.
323.
WiviottSD, BraunwaldE, McCabeCH, MontalescotG, RuzylloW, GottliebS, NeumannFJ, ArdissinoD, De ServiS, MurphySAet al.Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 357:2001–2015. 2007.
324.
WoulfeDS. Platelet G protein-coupled receptors in hemostasis and thrombosis. J Thromb Haemost, 3:2193–2200. 2005.
325.
WoulfeDS. Akt signaling in platelets and thrombosis. Expert Rev Hematol, 3:81–91. 2010.
326.
YanceyPG, BortnickAE, Kellner-WeibelG, de laLlera-Moya M, PhillipsMC, RothblatGH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol, 23:712–719. 2003.
ZeigerF, StephanS, HoheiselG, PfeifferD, RuehlmannC, KokschM. P-Selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease. Blood Coagul Fibrinolysis, 11:723–728. 2000.
330.
ZhangG, HanJ, WelchEJ, YeRD, Voyno-YasenetskayaTA, MalikAB, DuX, LiZ. Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J Immunol, 182:7997–8004. 2009.
331.
ZhengW, McLerranDF, RollandB, ZhangX, InoueM, MatsuoK, HeJ, GuptaPC, RamadasK, TsuganeSet al.Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med, 364:719–729. 2011.
332.
ZouMH, UllrichV. Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. FEBS Lett, 382:101–104. 1996.
333.
ZwaalRF, SchroitAJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood, 89:1121–1132. 1997.
334.
ZymekP, BujakM, ChatilaK, CieslakA, ThakkerG, EntmanML, FrangogiannisNG. The role of platelet-derived growth factor signaling in healing myocardial infarcts. J Am Coll Cardiol, 48:2315–2323. 2006.
